



DATE	STOCK	RECOMD	ENTRY PRICE	TARGET	STOP LOSS
7.6.2021	HDFCLIFE	BUY	680	705	665
7.6.2021	PEL	BUY	1928	2010	1850
7.6.2021	TATAMOTORS	BUY	334	360	315

NOTE –These Stocks are recommended only for short term investment (Stop Loss should be followed Daily closing basis).

TECHNICAL OUTLOOK

NIFTY WEEKLY CLOSE – 15670.25 (↑ 234.60)

Last week Nifty continued the positive momentum and moved higher to mark a record high of 15733. Nifty closed the week at a record level 15670 with a gain of 234 points.

Nifty remains above its key daily as well as weekly EMAs. Daily as well as weekly RSI is also placed above respective averages. Daily RSI is moving towards an over-bought zone.

Nifty faced some resistance near 15700 in the last week. Going ahead, if Nifty sustains above this level, it would move towards 15800. On the other hand, if profit-booking emerges, Nifty would seek immediate support at 15400 below which support is placed at 15175.





WEEKLY INVESTMENT IDEAS REVIEW

DATE	STOCK	RECOMD	ENTRY PRICE	TARGET	STOP LOSS	TODAY CLOSE	NET CHANGE (%)	REMARK
31.5.2021	ICICIGI	BUY	1484	1560	1450	1447.50	-2.52	Stop Loss Hit
31.5.2021	MUTHOOTFIN	BUY	1266	1310	1230	1509.35	16.12	Target Achieved
31.5.2021	RELIANCE	BUY	2094	2175	2000	2190.50	4.41	Target Achieved

WEEKLY MARKET REVIEW

Sensex settles above 52,000; Nifty above 15,600

Indian equity indices ended with modest gains during the week. Sentiment was positive as fresh covid cases continue to decline and vaccination pace picks up. The Nifty index scaled fresh record highs multiple times during the week. Both the Sensex and the Nifty, attained record closing high, on Thursday. The broader market outperformed their larger peers.

In the week ended on Friday, 4 June 2021, the Sensex rose 677.17 points or 1.32% to settle at 52,100.05. The Nifty 50 index gained 234.60 points or 1.52% to settle at 15,670.25. The BSE Mid-Cap index advanced 849.66or 3.92% to settle at 22,511.49. The BSE Small-Cap index rallied 783.21 points or 3.34% to settle at 24,261.90.

Reliance Industries (RIL) galloped 4.57%. RIL has initiated the proceedings of carving out its O2C businesses into a separate subsidiary and the process is expected to be completed in CY 2021.

Eicher Motors advanced 3.95%. VE Commercial Vehicles (VECV), the unlisted subsidiary of Eicher Motors, sold 1,223 units in May 2021, down by 43% as compared with 2,145 units sold in April 2021.

Tata Motors spurred 5.02%. Total sales in May 2021 stood at 26,661 vehicles, down by 36% from 41,858 vehicles sold in April 2021.

Mahindra & Mahindra (M&M) declined 4.94%. Its overall auto sales of May 2021 stood at 17,447 vehicles a decline of 52.1% from 36,437 units sold in April 2021.

Maruti Suzuki India rallied 3.71%. Total sales of 46,555 units in May 2021 compared with 18,539 units sold in May 2020. On a sequential basis, total sales declined 70.85% in May 2021 as compared to 1,59,691 units sold in April 2021.

Bajaj Auto rose 1.16%. The 2-wheeler maker's total sales surged 114% to 2,71,862 units in May 2021 as against 1,27,128 units sold in May 2020.

Hero MotoCorp gained 1.92%. The two-wheeler major's total two-wheeler sales increased 62.44% to 1,83,044 units in May 2021 as against 1,12,682 units in May 2020.

Coal India climbed 4.26%. On a provisional basis, the company's coal production rose 1.7% to 42.10 million tonnes while its coal off-take surged 37.6% to 55.10 million tonnes in May 2021 over May 2020.

ITC slipped 1.90%. The tobacco major's standalone net profit declined 1.3% to Rs 3,748.41 crore on 22.7% jump in net sales to Rs 13,161.11 crore in Q4 FY21 over Q4 FY20. EBITDA grew 7.4% year on year to Rs4,473 crore in Q4 FY21 over Q4 FY20.

Adani Ports and Special Economic Zone (APSEZ) surged 7.46%. The company said it handled cargo volume of 25.65 MMT in May 2021, registering a growth of 79% on year on year basis.

Sun Pharmaceutical Industries added 0.68%. The company has entered into a license agreement with Ferring Pharmaceuticals to commercialize obstetric drug, Caritec in India".

Meanwhile, the global economic outlook is improving as vaccine rollouts allow businesses to resume operations and as the United States pumps trillions of dollars into the world's largest economy, as per the Organisation for Economic Cooperation and Development (OECD). The global economy is set to grow 5.8% this year and 4.4% next year.

Source: www.capitalmarket.com



SAJAG SECURITIES PVT. LTD.

MEMBER: NATIONAL STOCK EXCHANGE OF INDIA LTD.

MEMBER: BOMBAY STOCK EXCHANGE LTD.

DEPOSITORY PARTICIPANT: NATIONAL SECURITIES DEPOSITORY LTD.

DEPOSITORY PARTICIPANT: CENTRAL DEPOSITORY SERVICES LTD.

33/15 - B, KARVE ROAD, REGENT CHAMBERS, PUNE - 411004, TEL: 91-20-66014737, FAX: 91-20-25302555

email: business@sajag.co.in / investorgrievance@sajag.co.in

NSE TM ID - 07549

BSE TM ID - 3105

NSDL DP ID: IN303647

CDSL DP ID: 12062400

SEBI Regn. No. INZ000221337

Disclosure: This report is issued by Sajag Securities Pvt. Ltd. (SSPL), a stock broking company, which is regulated by SEBI and its research activities are as per SEBI Guidelines for Research Analysts December 2014. Registration Number: INH000001923. This report is prepared and distributed by SSPL for information purpose only. SSPL and the research analyst(s) who prepared this report do not have any long or short positions in derivatives markets in any of the above mentioned securities. SSPL or the research analyst(s) do not have ownership of 1% or more in the company. The research analyst(s) who prepared this research report hereby certifies that the views expressed in this research report accurately reflect the research analyst's personal views about all of the subject issuers and/or securities, that the analyst(s) have no known material conflict of interest and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific views or recommendations contained in this research report.

Disclaimer: Neither the information contained herein nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the purchase or sale of any security or investment or derivatives. The information and opinions contained in the report were considered by SSPL to be valid when published. The report also contains information provided to SSPL by third parties. The source of such information will usually be disclosed in the report. While SSPL has taken all responsible steps to ensure that this information is correct, SSPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his/her own risk and SSPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily a guide to future performance. The report does not have regard to the specific investment objective, financial situation and the particular needs of any specific person who may receive this report. Investor must undertake independent analysis with their own legal, tax and financial advisors and reach their own decision regarding the appropriateness of investing in any securities or investment strategies discussed and recommended in this report and should understand that statements regarding future prospects may not be realized. In no circumstances be it used or considered as an offer to sell or a solicitation of any offer to buy or sell the securities mentioned in it. The information contained in the research reports may have been taken from trade and statistical services and other sources, which we believe reliable. SSPL does not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinions expressed reflect judgments at this date and are subject to change without notice. The target prices mentioned in the report are based on certain assumptions as of the date appearing in the material and may be subject to change from time to time without notice.